about
Belatacept in Kidney Transplantation of Moderately Sensitized PatientsCytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell TransplantTCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated DonorsDonor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsComparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationA Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi AnemiaHaplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood DisordersStem Cell Transplant (SCT) for Dyskeratosis Congenita or SAAA Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney TransplantationPurine Analog-Based Conditioning in Patients With Severe Aplastic AnemiaAllogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenStudy of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid WithdrawalHybrid Immunotherapy for Hemophagocytic LymphoHistiocytosisDonor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesFludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesPreemptive Therapy of GVHDThymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)Allogeneic Transplantation in Patients With Cutaneous T-Cell LymphomaAllogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)Comparison of ATG to Thymoglobuline in Renal TransplantationStudy of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister DonorNon-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesSafety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant RecipientsThymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell TransplantConditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationAutologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune DiseasesFlu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning RegimensProspective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic AnaemiaBone Marrow Transplantation in Young Adults With Severe Sickle Cell DiseaseZevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)Autologous Stem Cell Systemic Sclerosis Immune Suppression TrialEvaluate Effects and Safety of Pre-load Myfortic® in Transplant PatientsCalcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet TransplantationResearch Study of ATG and Rituximab in Renal TransplantationEfficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium MycophenolateDe Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab InductionThymoglobulin Induction in Kidney Transplant Recipients
P4844
Q61894370-DF08306A-C14B-453B-A77D-5A6E0776A21CQ61902423-A2B38A0B-E37B-4091-B88A-E7D422196C91Q61904950-78320021-13BB-48D2-ADBF-2D38A57FA1DBQ61904952-FE5934E7-7057-4D66-8CE2-5A42B86EB4EFQ61907523-00573506-3DA6-4BB4-9BD3-EC137630727CQ61907674-CCEC32CB-CBEE-4788-A45F-0FC22625484FQ61907988-5DE2F426-81A2-462E-A9F6-AADC20A638A3Q61918157-0CBC783A-4240-4A5F-BCC7-BB4E32B132E8Q61920640-E10311FA-1D55-4DE9-864C-04CA6AB19307Q61920664-C2A8ACD3-5F36-49F9-B30C-6FCFAFA94054Q61921359-7D3FA095-8A91-42D0-95F4-1C4FE827D184Q61923784-EF0873F1-3D44-4190-BD7C-E294E4A3950AQ61932472-B5F2E127-980E-48A0-A023-9001F38B0DC7Q61935729-EECE66A1-5BB6-47C2-BDF9-46A0691B37B3Q61936868-CC861FCF-AAC9-47CB-868A-A4D4552AFE8DQ61955568-FCBEA268-25B8-4C4E-B844-995209971F5DQ61955600-1DAAEDD9-DD13-4625-B760-E515AAB8E001Q61969738-3E1BAADA-C418-495E-A0F6-12CDEA4E6442Q61979854-37A0F2A8-039F-4C85-9786-76F1C70A07A5Q61979928-0FBD1178-2AD8-484E-9B14-20F0BB662A6DQ61981266-7FE328C9-C3B7-4752-9FDF-3A46F45CFBC3Q61981396-7C6EBA47-D34C-41DA-A873-B16C9972AE0FQ62042723-D7F7A40D-157E-40B2-8E2B-284DEF9CAF1FQ62104929-9763E025-3F8F-4515-A03D-DF59E5097E5CQ62104978-CD57D684-3B24-4778-81C7-8632CD5C1923Q62110189-29264803-021C-4668-947A-D7C70B441674Q62819286-0EE70449-2B4E-4D78-899A-AFED68A37AEBQ63062600-4AA1B6D1-B7A3-4CD3-B165-8255C376CB71Q63063171-1B5D636D-74AC-40CD-A363-2DA0FDF1C4B4Q63316388-3821E31A-3C94-4B2C-9F52-3B6DA608C109Q63317038-0B29CE94-2169-4C25-B261-F8E5DD41B774Q63318690-D1004EE4-CD74-4A22-A6BB-8B44133C5FA1Q63320747-DF74D78B-4C2B-4D42-853D-DC77595FBD49Q63321630-8FA52463-64A8-4E51-82F5-4912E4123C07Q63335948-EC2DD2B7-658D-430F-97B6-9FE91D80FA8EQ63336197-A3A9C906-86D0-43C9-BE6B-0E1710DEBB1EQ63337168-94F5E017-ABE6-440A-8B92-39CE0EF59F1AQ63337595-15E5E1D5-6FCB-4D77-B273-EA54EE354EFBQ63339058-89A51321-20C6-48ED-B88F-BAA694B16559Q63340376-9FD7699C-C032-4906-A818-FC0BDF90712E
P4844
description
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
composé chimique
@fr
name
Anti-thymocyte Globulin (Rabbit)
@en
type
label
Anti-thymocyte Globulin (Rabbit)
@en
altLabel
Anti-thymocyte globulin (rabbit)
@en
Thymoglobulin
@en
rATG
@en
rabbit ATG
@en
prefLabel
Anti-thymocyte Globulin (Rabbit)
@en